Gene therapy’s breakout moment

March SyringeWithDNA GeneTherapyWilsonBioP e
Credit: Mopic - Fotolia.com via GEN

The following is an excerpt.

Venture capital interest in funding gene therapies and the companies that develop them has dramatically increased judging by a recent spurt of activity, a lot of due diligence, a few deals announced, and a few more in the works and expected to be announced soon.

What does all that activity mean? First, there’s enough clinical data out there to validate the concept of gene therapy. The more speculative venture capital investors, rather than the pharmaceutical industry, are realizing the potential of this and are getting into the game.

View the original article here: Is This Gene Therapy’s Breakout Moment?

ADVERTISEMENT

Additional resources:

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend